Mutations of the β myosin heavy chain gene in hypertrophic cardiomyopathy: Critical functional sites determine prognosis

Heart

Volumn 89, Issue 10, 2003, Pages 1179-1185

  Woo, A ^a,b   Rakowski, H ^b   Liew, J C ^b   Zhao, M S ^b   Liew, C C ^b   Parker, T G ^b   Zeller, M ^b   Wigle, E D ^b   Sole, M J ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MYOSIN HEAVY CHAIN; MYOSIN SUBFRAGMENT;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; EVALUATION; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; GENOTYPE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MORTALITY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN STRUCTURE; SURVIVAL RATE; SURVIVAL TIME; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; COHORT STUDIES; CONSERVED SEQUENCE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYOSIN HEAVY CHAINS; PEDIGREE; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS;

EID: 0141719865     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001;104:557-67.
2. Wigle ED. The diagnosis of hypertrophic cardiomyopathy. Heart 2001;86:709-14.
3. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-20.
4. Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, part I. Circulation 2001;104:2113-16.
5. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001;33:655-70.
6. Jarcho JA, McKenna W, Pare JAP, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 1989;321:1372-8.
7. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108-14.
8. Sorajja P, Elliott PM, McKenna WJ. The molecular genetics of hypertrophic cardiomyopathy: prognostic implications. Europace 2000;2:4-14.
9. Maron BJ, Moller JH, Seidman CE, et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. A statement for healthcare professionals from the councils on clinical cardiology, cardiovascular disease in the young, and basic science, American Heart Association. Circulation 1998;98:1460-71.
10. Ackerman MJ, Van Driest SL, Ommen SR, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Call Cardiol 2002;39:2042-8.
11. Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophic cardiomyopathy: insights provided by comparisons of kindreds with distinct and identical β-myosin heavy chain gene mutations. Circulation 1994;89:22-32.
12. Rayment I, Rypniewski WR, Schmidt-Bäse K, et al. Three-dimensional structure of myosin subfragment-1: a molecular motor. Science 1993;261:50-8.
13. Rayment I, Holden HM, Sellers J, et al. Structural interpretation of the mutations in the β-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 1995;92:3864-8.
14. Erdmann J, Raible J, Maki-Abadi J, et al. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol 2001;38:322-30.
15. Niimura H, Patton KK, McKenna WJ, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 2002;105:446-51.
16. Rakowski H, Sasson Z, Wigle ED. Echocardiographic and Doppler assessment of hypertrophic cardiomyopathy. J Am Soc Echocardiogr 1988;1:31-47.
17. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy: the importance of the site and extent of hypertrophy: a review. Prog Cardiovasc Dis 1985;28:1-83.
18. Romhilt, DW, Estes EH Jr. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am Heart J 1968;75:752-8.
19. Charron P, Dubourg O, Desnos M, et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. Circulation 1997;96:214-9.
20. McKenna WJ, Spirito P, Desnos M, et al. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 1997;77:130-2.
21. Humez FU, Houston AB, Watson J, et al. Age and body surface area related normal upper and lower limits of M mode echocardiographic measurements and left ventricular volume and mass from infancy to early adulthood. Br Heart J 1994;72:276-80.
22. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995;332:1058-64.
23. Yamauchi-Takihara K, Sole MJ, Liew J, et al. Characterization of human cardiac myosin heavy chain genes. Proc Natl Acad Sci USA 1989;86;3504-8.
24. Liew CC, Sole MJ, Yamauchi-Takihara K, et al. Complete sequence and organization of the human cardiac β-myosin heavy chain gene. Nucleic Acids Res 1990;18:3647-51.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Star Assoc 1958;53:457-81.
26. Cox DR. Regression models and life-tables. J R Star Soc [B] 1972;34:187-220.
27. Van Driest SL, Ackerman MJ, Ommen SR, et al. Prevalence and severity of "benign" mutations in the β-myosin heavy chain, cardiac troponin T, and α-tropomyosin genes in hypertrophic cardiomyopathy. Circulation 2002;106:3085-90.
28. Arg→Gln mutation. Circulation 1992;86:345-52.
29. Redwood CS, Moolman-Smook JC, Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 1999;44:20-36.
30. Tyska MJ, Hayes E, Giewat M, et al. Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ Res 2000;86:737-44.
31. Yamashita H, Tyska MJ, Warshaw DM, et al. Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. J Biol Chem 2000;275:28045-52.
32. Atiga WL, Fananapazir L, McAreavey D, et al. Temporal repolarization lability in hypertrophic cardiomyopathy caused by β-myosin heavy-chain gene mutations. Circulation 2000;101:1237-42.
33. Nagueh SF, Kopelen HA, Lim DS, et al. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2000;102:1346-50.
34. Jaaskelainen P, Soranta M, Miettinen R, et al. The cardiac β-myosin heavy chain gene is not the predominant gene for hypertrophic cardiomyopathy in the Finnish population. J Am Coll Cardiol 1998;32:1709-16.
35. Tesson F, Richard P, Charron P, et al. Genotype-phenotype analysis in four families with mutations in β-myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy. Hum Mutat 1998;12:385-92.
36. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998;338:1248-57.
37. Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 2001;38:315-21.
38. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-8.
39. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73.
40. Lechin M, Quiñones MA, Omran A, et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 1995;92:1808-12.
41. Patel R, Lim DS, Reddy D, et al. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000;32:2369-77.